48
Participants
Start Date
March 17, 2022
Primary Completion Date
March 31, 2025
Study Completion Date
March 31, 2025
AZD4205
AZD4205 capsules administered at 150 mg orally, once daily, in 28-day cycle.
Anhui Provincial Hospital (The First Affiliated Hospital of USTC), Hefei
Peking university Third Hospital, Beijing
The First Affiliated Hospital of Chongqing Medical University, Chongqing
Guangdong Provincial People's Hospital, Guangzhou
Sun Yat-sen University Cancer Center, Guangzhou
The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai
Hainan General Hospital, Haikou
The Fourth Hospital of Hebei Medical University, Shijiazhuang
Henan Cancer Hospital, Zhengzhou
Hubei Cancer Hospital, Wuhan
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan
Hunan Cancer Hospital, Changsha
Research Center of Clinical Trials, The Third Xiangya Hospital of Central South University, Changsha
The Affiliated Hospital of Inner Mongolia Medical University, Hohhot
The First Affiliated Hospital of Nanchang University, Nanchang
The Second Affiliated Hospital of Nanchang University, Nanchang
Shandong Cancer Hospital & Institution, Jinan
Linyi Cancer Hospital, Linyi
Shanxi Provincial Cancer Hospital, Taiyuan
West China Hospital of Sichuan University, Chengdu
Tianjin Medical University Cancer Institute & Hospital, Tianjin
Yunnan Cancer Hospital, Kunming
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou
Lead Sponsor
Dizal Pharmaceuticals
INDUSTRY